Chromatin/Epigenetics
Chromatin/epigenetics inhibitors are compounds that modulate the structure and function of chromatin or interfere with epigenetic modifications, such as DNA methylation and histone modification. These inhibitors are essential tools for studying gene expression regulation and the role of epigenetics in diseases like cancer, neurological disorders, and developmental abnormalities. By targeting epigenetic processes, these inhibitors can alter gene expression patterns and offer new therapeutic avenues. At CymitQuimica, we provide a wide selection of high-quality chromatin/epigenetics inhibitors to support your research in molecular biology, genetics, and epigenetics.
Subcategories of "Chromatin/Epigenetics"
Found 2612 products of "Chromatin/Epigenetics"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
HDAC-IN-41
CAS:HDAC-IN-41 is a selective class I HDAC inhibiting HDAC1, 2, & 3 with IC50: 0.62-1.46 µM; oral use; has NO-release.Formula:C20H22N4O6SColor and Shape:SolidMolecular weight:446.48PARP11 inhibitor ITK7
CAS:ITK7 is a potent, selective PARP11 inhibitor with an IC50 of 14 nM, useful for cellular localization research.Formula:C17H14N4OSColor and Shape:SolidMolecular weight:322.38HDAC1/MAO-B-IN-1
CAS:HDAC1/MAO-B-IN-1 is a selective Alzheimer’s research inhibitor with IC50s: HDAC1 (21.4 nM) & MAO-B (99 nM); crosses the blood-brain barrier.Formula:C18H17ClN2O2Color and Shape:SolidMolecular weight:328.79Aurora kinase inhibitor-9
CAS:Aurora kinase inhibitor-9 (9d) targets AURKA/B with IC50: 0.093 μM for A and 0.09 μM for B, with wide anti-proliferative effects.Formula:C19H17Cl2N3O4SColor and Shape:SolidMolecular weight:454.33BET-IN-7
CAS:BET-IN-7 is a potent BET inhibitor with a Ki of 12.27 μM and Kd of 89.3 μM, useful in sepsis research.Formula:C18H12ClN3OSColor and Shape:SolidMolecular weight:353.83KDM2B-IN-4
CAS:KDM2B-IN-4, from patent WO2016112284A1 as 182b, is a potent KDM2B inhibitor used in cancer research.Formula:C24H28N2O2Color and Shape:SolidMolecular weight:376.49Dihydro-5-azacytidine acetate
CAS:Dihydro-5-azacytidine acetate (DHAC), a nucleoside analog, becomes integrated into DNA, thereby inhibiting DNA methylation, and exhibits antitumor activity [1Formula:C10H18N4O7Purity:98%Color and Shape:SolidMolecular weight:306.27BETi-211
CAS:BETi-211 is a selective inhibitor BET bromodomain.Formula:C26H29N7O3Color and Shape:SolidMolecular weight:487.55OUL245
CAS:OUL245: A selective PARP2 inhibitor (IC50=44nM), also inhibits other PARPs/TNKS (IC50=2.9-8.8μM).Formula:C8H5N3OSColor and Shape:SolidMolecular weight:191.21HDAC6-IN-15
HDAC6-IN-15: selective HDAC6 inhibitor, IC50 of 38.2 nM, for cancer and neurodegenerative research.Formula:C25H28FFeN3O2Color and Shape:SolidMolecular weight:477.35CYP51/HDAC-IN-1
CAS:Orally active CYP51/HDAC-IN-1 dual inhibitor targets virulence factors and resistance genes; effective against Candidiasis and Cryptococcal meningitis.Formula:C30H40F2N6O4Color and Shape:SolidMolecular weight:586.67CBB1003
CAS:CBB1003 is a new inhibitor of histone demethylase LSD1 (IC50: 10.54 μM).Formula:C25H31N9O4Purity:98%Color and Shape:SolidMolecular weight:521.57IND 1316
CAS:IND 1316 is an activator of AMP-activated protein kinase (AMPK).Formula:C22H17NO3Color and Shape:SolidMolecular weight:343.38PKN1/2-IN-1
CAS:PKN1/2-IN-1 is a potent and selective PKN2 inhibitor, membrane permeability and anticancer.Protein kinase N proteins (PKN) are effectors of Rho GTPases.Formula:C14H15N3OPurity:99.72%Color and Shape:SolidMolecular weight:241.29Ref: TM-T60339
2mg137.00€5mg222.00€10mg356.00€25mg708.00€50mg1,063.00€100mg1,674.00€1mL*10mM (DMSO)245.00€SMTIN-T140
CAS:SMTIN-T140: strong TRAP1 inhibitor, IC50=1.646μM, anticancer; disrupts mitochondria, boosts ROS, activates AMPK, shrinks PC3 tumors, no in vivo toxicity.Formula:C36H34BrClFN5OPPurity:98%Color and Shape:SolidMolecular weight:718.02HDAC-IN-28
CAS:HDAC-IN-28 is a novel inhibitor of HDAC that significantly inhibits tumour growth and metastasis.Formula:C23H26N4O4SColor and Shape:SolidMolecular weight:454.54Y08175
CAS:Y08175, a CBP Bromodomain inhibitor, IC50: 37 nM (AlphaScreen), 178.15 nM (HTRF). Useful in prostate cancer research.Formula:C23H19FN4O5Color and Shape:SolidMolecular weight:450.42CEP-8983
CAS:CEP-8983 is a PARP inhibitor potentially for the treatment of solid tumours.Formula:C18H14N2O3Purity:98%Color and Shape:SolidMolecular weight:306.32JS1310
CAS:JS1310 is a selective PRMT7 inhibitor (IC50: 5 μM against human PRMT7). JS1310 has shown anti-cancer effects on different cancer cells.Formula:C23H22FN5O3Color and Shape:SolidMolecular weight:435.45ARTD10/PARP10-IN-2
CAS:ARTD10/PARP10-IN-2: A potent, non-selective PARP inhibitor, IC50: ARTD10/PARP10 (2.0μM), ARTD1/PARP1 (9.7μM).Formula:C12H13N3O3Color and Shape:SolidMolecular weight:247.25OHM1
CAS:OHM1, an analog of HIF1α CTAD, effectively inhibits the interaction between HIF1α CTAD and p300/CBP by targeting the CH1 domain with a binding affinity of 0.53Formula:C24H42N6O5Color and Shape:SolidMolecular weight:494.63PARP1-IN-11
CAS:PARP1-IN-11 is a potent PARP1 inhibitor (IC50=0.082 μM), also reducing PARP3, TNKS1, and TNKS2 activity.Formula:C16H12N2O4Color and Shape:SolidMolecular weight:296.28SDR-04
CAS:SDR-04 inhibits BRD4-BD1 with high affinity, suppressing MV4;11 cancer cell growth as a BET inhibitor.Formula:C19H16N4O2Color and Shape:SolidMolecular weight:332.36CP-690550A
CAS:Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.Formula:C15H21N5O2Color and Shape:SolidMolecular weight:303.36ABT-472
CAS:ABT-472 is a novel PARP inhibitorFormula:C20H28N4O5Color and Shape:SolidMolecular weight:404.46CBHA
CAS:m-Carboxycinnamic bishydroxamide: HDAC inhibitor, ID50 = 10 nM (HDAC1), 70 nM (HDAC3), induces apoptosis and tumor growth suppression.Formula:C10H10N2O4Color and Shape:SolidMolecular weight:222.2CSV0C018875
CAS:CSV0C018875 is a quinoline-based EHMT2/G9a inhibitor with lower cytotoxicity than BIX-01294 [1].Formula:C18H17ClN2OColor and Shape:SolidMolecular weight:312.79(2R,5S)-Ritlecitinib
CAS:(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective inhibitor of JAK3 with IC 50 of 144.8 nM[1].Formula:C15H19N5OColor and Shape:SolidMolecular weight:285.34BRD4-BD1-IN-1
CAS:BRD4-BD1-IN-1 (Compound 9a) is a BRD4-BD1 inhibitor(IC50= 38.20 μM).Formula:C16H15BrN4O4Color and Shape:SolidMolecular weight:407.22TP-238
CAS:"TP-238: Potent CECR2/BPTF dual probe; IC50: 30 nM/350 nM. Inhibits BRD9 (pIC50: 5.9); minimal activity on 338 other kinases."Formula:C22H30N6O3SColor and Shape:SolidMolecular weight:458.58JAK1-IN-4
CAS:JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).Formula:C26H32FN9O2Purity:98%Color and Shape:SolidMolecular weight:521.59BRD4 Inhibitor-26
BRD4 Inhibitor-26: blocks BRD4 (BD1 and BD2) with IC50 of 0.82 μM & 1.94 μM; used in ovarian cancer research.Formula:C29H27N5O6SColor and Shape:SolidMolecular weight:573.62CeMMEC2
CAS:CeMMEC2, a novel inhibitor of BRD4, binds both the first and the second bromodomain of BRD4.Formula:C14H19N5Color and Shape:SolidMolecular weight:257.33HDAC6/8/BRPF1-IN-1
CAS:HDAC6/8/BRPF1-IN-1 is a cancer-research inhibitor for HDAC6, HDAC8, BRPF1 with IC50: 344-908 nM and Kd: 175.2 nM.Formula:C18H17N3O5SColor and Shape:SolidMolecular weight:387.41Povorcitinib
CAS:Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP).Formula:C23H22F5N7OColor and Shape:SolidMolecular weight:507.469ART-IN-1
CAS:ART-IN-1 (compound 7) is a selective inhibitor of PARP with IC 50 s of 19, 22, 2.4, >100, 1.1 μM for PARP2, TNKS2, PARP10, PARP14, PARP15, respectively [1].Formula:C14H13NO2SColor and Shape:SolidMolecular weight:259.32MAT2A-IN-7
CAS:MAT2A-IN-7 inhibits MAT2A in various cancers, especially MTAP-deficient cancer cells, with potential for research use.Formula:C17H13ClF3N3O2Color and Shape:SolidMolecular weight:383.75SRTCX1003
CAS:SRTCX1003, a SIRT1 activator, suppresses inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB activity.Formula:C23H23N5O3SColor and Shape:SolidMolecular weight:449.53Aurora Kinases-IN-3
CAS:Aurora Kinases-IN-3 is an oral AURKB inhibitor that disrupts its mitotic localization, not its H3 Ser10 phosphorylation.Formula:C20H16F3N3O4Color and Shape:SolidMolecular weight:419.35PBRM1-BD2-IN-6
CAS:PBRM1-BD2-IN-6: potent PBRM1 inhibitor with 0.22 µM IC50, anti-cancer research potential.Formula:C16H15ClN2OColor and Shape:SolidMolecular weight:286.76A2AAR/HDAC-IN-2
CAS:A2AAR/HDAC-IN-2: potent dual A2AAR/HDAC inhib., Ki 10.3 nM, IC50 18.5 nM, anti-tumor potential.Formula:C23H26N6O4Color and Shape:SolidMolecular weight:450.49KCN1
CAS:KCN1: a synthetic sulfonamide, nanomolar HIF inhibitor with preclinical anti-glioma and anti-pancreatic cancer effects.Formula:C26H27NO5SColor and Shape:SolidMolecular weight:465.56SIRT2-IN-10
CAS:SIRT2-IN-10 (Compound 12) is a potent inhibitor of SIRT2 (IC50: 1.3 μM), which can be used in the study of cancer and neurodegenerative diseases.Formula:C28H21N5OSColor and Shape:SolidMolecular weight:475.56Trotabresib
CAS:Trotabresib (CC-90010) is an orally active inhibitor of BET and can be used in studies about advanced solid tumors.Formula:C21H21NO4SPurity:99.86%Color and Shape:SolidMolecular weight:383.46Ref: TM-T36395
1mg92.00€5mg188.00€10mg311.00€25mg528.00€50mg755.00€100mg1,017.00€1mL*10mM (DMSO)215.00€GPI-15427
CAS:GPI-15427: a potent PARP-1 inhibitor, crosses the blood-brain barrier, boosts TMZ's effects on CNS tumors, and sensitizes cancer to radiotherapy.Formula:C20H20N4O2Color and Shape:SolidMolecular weight:348.4CPI-1612
CAS:CPI-1612: Oral EP300/CBP HAT inhibitor, IC50 8.1 nM, has anticancer properties.Formula:C27H26N6OColor and Shape:SolidMolecular weight:450.53ZLD2218
CAS:ZLD2218, a potent inhibitor of BRD4 with an IC50 value of 107 nM, has been demonstrated to mitigate kidney injury and fibrosis through extensive studies.Formula:C22H18N4OColor and Shape:SolidMolecular weight:354.4BRM/BRG1 ATP Inhibitor-3
CAS:BRM/BRG1 ATP Inhibitor-3 targets BRM/BRG1 (IC50: 10.4/19.3 nM) for cancer/BAF disorder research.Formula:C26H25N5O2S2Color and Shape:SolidMolecular weight:503.64PF-00956980
CAS:PF-00956980: reversible JAK inhibitor, IC50: JAK1 (2.2μM), JAK2 (23.1μM), JAK3 (59.9μM), for lung/skin inflammation research.Formula:C18H26N6OColor and Shape:SolidMolecular weight:342.44CBP/p300-IN-10
CAS:CBP/p300-IN-10, potent EP300/CREBBP inhibitor; IC50: 26 nM/39 nM. Potential for cancer research.Formula:C25H24F5N5O3Color and Shape:SolidMolecular weight:537.48
